Interaction in Chronic Obstructive Pulmonary Disease Experiment

• Status: Completed
• Trial end date: 2011-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The final purpose of this study is to determine whether bronchodilation and cigarette smoking in Chronic Obstructive Pulmonary Disease (COPD) patients interact, resulting in an increase of cardiovascular disease. The aim of this part of the study is to demonstrate the basic mechanism: Does increased respiratory function after administration of a bronchodilator in patients with COPD lead to elevated pulmonary retention of the harmful compounds in inhaled cigarette smoke and to short-term biological effects associated with cardiovascular disease?

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Radboud University
• Treatments: Albuterol; Tiotropium Bromide

Criteria

Inclusion Criteria:

• COPD Gold stage II-III (FEV1/FVC<0,70 and FEV1 30-80% of predicted value).

• Current cigarette smoking (at the time of performing the study).

• Willing to provide written informed consent.

• Refrain from smoking and bronchodilators > 8 hours (depends on treatment) before the test.

• Registered in one of the recruitment institutes.

Exclusion Criteria:

• COPD gold stage I or IV.

• Asthmatic component: History of asthma, present asthma by complaints, eosinophilia or reversibility ≥ 10% of predicted.

• Unable to communicate.

• Physically unable to perform any of the tests.

• Non-COPD respiratory disorders.

• Previous lung-volume reduction surgery and/or lung transplantation.

• Evidence of alcohol, drug or solvent abuse.

• Known α-1 antitrypsin deficiency.